Alibaba
BABA
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
Apple
AAPL
US Stock MarketDetailed Quotes
LEXX Lexaria Bioscience
- 1.6000
- +0.0700+4.58%
Close Feb 14 16:00 ET
- 1.6200
- +0.0200+1.25%
Post 20:01 ET
28.08MMarket Cap-3.20P/E (TTM)
1.7200High1.5600Low173.84KVolume1.5600Open1.5300Pre Close282.53KTurnover1.76%Turnover RatioLossP/E (Static)17.55MShares6.850052wk High2.87P/B15.81MFloat Cap1.500052wk Low--Dividend TTM9.88MShs Float12.5000Historical High--Div YieldTTM10.46%Amplitude0.6488Historical Low1.6250Avg Price1Lot Size
Lexaria Bioscience News
Lexaria Bioscience Granted Two New DehydraTECH Patents
Express News | Lexaria Granted Two US Patents For The Use Of DehydraTECH In Epilepsy Treatment
Express News | Lexaria Bioscience Corp. Begins Dosing In DehydraTECH GLP-1 Rodent Distribution Study
Express News | Lexaria Completes Submission To HREC For Planned Additional Of Study Arm 5 To Evaluate DehydraTECH-Tirzepatide Formulation
Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024
Lexaria Unveils 2025 R&D Plans Focused On GLP-1: To Finalize Human Pilot Study #3, Launch Phase 1b Study In Australia, Complete Human Pilot Study #5, Conduct Fluorescent Biodistribution Study, And Run Additional Animal Studies
Lexaria Releases Annual Letter From the CEO
Lexaria Bioscience Is Maintained at Buy by HC Wainwright & Co.
Lexaria Bioscience Analyst Ratings
H.C. Wainwright Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Cuts Target Price to $7
Lexaria Bioscience Price Target Lowered to $7 From $10 at H.C. Wainwright
Express News | Lexaria Bioscience Corp Files for Mixed Shelf of up to $50 Mln - SEC Filing
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Lexaria Bioscience Shares Are Trading Lower. The Company Announced Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings From Human Study GLP-1-H24-3.
Express News | Lexaria Bioscience Shares Are Trading Lower. The Company Announced Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings From Human Study GLP-1-H24-3
Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects
Express News | Lexaria's Announces Partial Findings Showing Oral DehydraTECH-Tirzepatide Produced Reduced Adverse Events Of 47% Compared To Injected Zepbound
Lexaria Bioscience Earnings Analysis: Q1 Recap
10-Q: Q1 2025 Earnings Report
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.